Vardenafil (Levitra/Staxyn): Compounded vs. Branded Comparison

What Is Vardenafil and How Does It Work?

Vardenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that increases cyclic GMP in penile smooth muscle, sustaining an erection in response to sexual stimulation. The drug does not create erections without arousal. Both branded and compounded versions share identical molecular targets.

Mechanism at the Receptor Level

PDE5 enzymes normally break down cyclic GMP in corpus cavernosum smooth muscle. Vardenafil blocks this breakdown competitively. The IC50 for PDE5 inhibition by vardenafil is approximately 0.7 nM, making it roughly 10-fold more potent at PDE5 than sildenafil in isolated enzyme assays, as reported in receptor-binding comparisons reviewed by Corbin and Francis (Porst et al., Int J Impot Res 2003). That biochemical potency does not automatically translate to superior clinical outcomes at usual doses, because clinical efficacy depends on tissue distribution, protein binding, and individual metabolism.

Pharmacokinetics: The Numbers That Matter

Vardenafil is absorbed rapidly after oral dosing. Peak plasma concentration (Tmax) occurs at about 0.7-0.9 hours under fasting conditions. Absolute bioavailability is approximately 15% owing to first-pass hepatic metabolism, primarily via CYP3A4 and, to a lesser extent, CYP3A5 and CYP2C9. The half-life is 4-5 hours (FDA label, Levitra, NDA 021389). Protein binding is about 95%, mainly to albumin and alpha-1-acid glycoprotein.

A high-fat meal reduces Cmax by approximately 18-50% depending on fat content. Staxyn's ODT formulation produces a Cmax roughly 1.3-fold higher than the Levitra film-coated tablet at the same 10 mg dose, because the ODT partly bypasses first-pass absorption through buccal mucosa (FDA label, Staxyn, NDA 022473).

Branded Vardenafil: Levitra and Staxyn

Levitra (vardenafil HCl) was approved by the FDA in August 2003 for the treatment of erectile dysfunction in adult men. Staxyn, the ODT version, received approval in June 2010. Both carry full FDA NDA approval, meaning every commercial lot has been manufactured under current Good Manufacturing Practices (cGMP) and tested for potency, dissolution, and sterility.

Levitra (Film-Coated Tablet)

Levitra is available in 5 mg, 10 mg, and 20 mg film-coated tablets. The recommended starting dose is 10 mg taken 25-60 minutes before sexual activity, no more than once per day. Dose adjustment to 5 mg is recommended for men older than 65 years and for those with moderate hepatic impairment (Child-Pugh B). The 20 mg dose is contraindicated in severe hepatic impairment (Child-Pugh C) (FDA label, Levitra).

Staxyn (Orally Disintegrating Tablet)

Staxyn delivers 10 mg of vardenafil in an ODT format that dissolves on the tongue without water. The higher Cmax relative to Levitra means that Staxyn is not dose-substitutable milligram for milligram with Levitra; the FDA label explicitly states the two formulations are not interchangeable (FDA label, Staxyn). Patients with phenylketonuria must avoid Staxyn because it contains aspartame.

Clinical Efficacy Data for Branded Vardenafil

The key trials for vardenafil used standardized endpoints including the International Index of Erectile Function (IIEF) and the Sexual Encounter Profile (SEP). In the trial by Porst et al. (Int J Impot Res 2003, N=601), vardenafil 20 mg produced successful vaginal penetration in 80% of attempts (SEP2) versus 52% placebo, and successful intercourse completion in 65% of attempts (SEP3) versus 36% placebo (Porst et al., 2003). The IIEF erectile function domain score improved by 8.0 points from baseline on vardenafil 20 mg versus 3.0 points on placebo (P<0.001).

Efficacy in diabetic men deserves specific attention because diabetes-related ED is notoriously harder to treat. In the Porst 2003 analysis of the diabetic subgroup, vardenafil 20 mg improved SEP3 success from 28% (placebo) to 57%, a near doubling of successful intercourse attempts even in men with significant neuropathy and vascular disease (Porst et al., 2003).

A pooled analysis of three Phase III trials (N=1,363) published in Urology confirmed that vardenafil 10 mg and 20 mg produced statistically significant improvements in all five IIEF domains compared with placebo, with an overall responder rate above 70% at the 20 mg dose in the general ED population (Goldstein et al., Urology 2003).

Compounded Vardenafil: What It Is and Where It Comes From

Compounded vardenafil is prepared by licensed 503A or 503B pharmacies under the framework of the Drug Quality and Security Act of 2013. These pharmacies can legally compound vardenafil for individual patients (503A) or in larger batches for office use (503B), provided they use pharmaceutical-grade bulk active ingredient. Compounding is not the same as generic manufacturing and does not require FDA approval of the final product.

503A vs. 503B Pharmacies

503A pharmacies compound on a patient-by-patient, prescription-specific basis. State boards of pharmacy oversee them primarily. 503B outsourcing facilities operate under stricter FDA cGMP-like oversight, must register with the FDA, and undergo regular inspections. For compounded vardenafil, a 503B source generally provides stronger quality assurance than a 503A source, though neither undergoes the same lot-release testing as a branded NDA product (FDA, Compounding Laws and Policies).

Available Compounded Formulations

Compounding pharmacies typically prepare vardenafil in several forms:

• Oral tablets (5 mg, 10 mg, 20 mg, and custom doses like 15 mg)
• Sublingual troches or lozenges, intended for faster mucosal absorption
• Transdermal creams, though absorption data for this route are very limited

The sublingual troche format is popular in telehealth channels because it is marketed as faster-acting. The pharmacokinetic claim is plausible given the buccal vascularity, but no peer-reviewed, controlled bioavailability study comparing compounded vardenafil troches to Levitra has been indexed on PubMed as of this writing.

Quality Control Gaps in Compounded Products

FDA inspection records and published analytical studies identify dose uniformity as the primary risk with compounded oral PDE5 inhibitors. A 2012 FDA survey of compounded products found that a meaningful proportion of tested lots failed potency specifications, with some containing less than 75% of labeled dose. These failures do not mean all compounded products are substandard, but they underscore the absence of the systematic release testing that backs every Levitra batch. Prescribers and patients should request a Certificate of Analysis (CoA) from the compounding pharmacy before dispensing.

Head-to-Head Comparison: Compounded vs. Branded

The table below summarizes the key differences clinicians and patients weigh when choosing a vardenafil formulation.

| Feature | Levitra (branded) | Staxyn (branded ODT) | Compounded vardenafil | |---|---|---|---| | FDA NDA approval | Yes | Yes | No | | Bioequivalence data | Full | Full (vs. Levitra) | None publicly available | | Dose flexibility | 5/10/20 mg | 10 mg only | Custom (e.g., 2.5-40 mg) | | Typical cost per unit | $50-$90 | $55-$95 | $3-$15 | | Formulation options | Oral tablet | ODT | Tablet, troche, transdermal | | cGMP lot-release testing | Yes | Yes | Partial (503B) or No (503A) | | Insurance coverage | Often partial | Often partial | Rarely covered | | Food interaction | 18-50% Cmax drop with high fat | Moderate | Unknown for most compounded forms |

Cost Differential and Access

The retail price of branded Levitra without insurance reaches $400-$500 for a 5-tablet pack of 20 mg tablets at major U.S. Pharmacies. Generic vardenafil (which became available after patent expiry) can reduce cost to $20-$60 per tablet depending on the pharmacy. Compounded vardenafil from a reputable 503B pharmacy typically runs $3-$15 per dose, making it the most accessible option for men without prescription drug coverage. The price advantage is significant and real.

However, the FDA does not permit compounding of a drug that is "essentially a copy" of a commercially available product unless the prescriber documents a patient-specific medical necessity (for example, a required dose not commercially available, or an allergen-free preparation) (FDA, Compounding Laws and Policies).

Dose Customization as a Medical Rationale

One legitimate clinical reason to use compounded vardenafil is the need for doses outside the commercial range. A 2.5 mg dose may benefit men with severe hepatic impairment or significant drug interactions (for example, moderate CYP3A4 inhibitors like erythromycin or fluconazole). A 15 mg dose may fill the gap between 10 mg (insufficient response) and 20 mg (side-effect burden). Compounding addresses these clinical niches that the branded products cannot serve.

Safety Profile: Where Branded and Compounded Differ

The pharmacological safety profile of vardenafil is the same regardless of source because the adverse events flow from the molecule's mechanism. The clinical risk differences between formulations arise from quality control rather than chemistry.

Class-Effect Adverse Events

Common adverse events from branded trial data include headache (15% at 20 mg), flushing (11%), rhinitis (9%), and dyspepsia (4%), versus 4%, 1%, 1%, and 1% placebo respectively, based on the Porst 2003 trial population (Porst et al., 2003). Transient visual disturbances (blue-green hue, blurred vision) occur in less than 2% of patients and are related to mild PDE6 inhibition in retinal photoreceptors.

Vardenafil produces a mean QTc prolongation of approximately 8 ms at the 10 mg dose and 10 ms at the supratherapeutic 80 mg dose, based on a thorough QT study referenced in the FDA label (FDA label, Levitra). This is clinically relevant for patients also taking Class IA antiarrhythmics (quinidine, procainamide) or Class III agents (amiodarone, sotalol), where co-administration is contraindicated.

The Nitrate Contraindication

All PDE5 inhibitors are absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) or nitric oxide donors because the combination can cause severe, potentially fatal hypotension (FDA label, Levitra). This contraindication applies to every vardenafil source, branded or compounded.

Compounding-Specific Safety Considerations

The key compounding-specific risk is dose inaccuracy. If a compounded troche contains 150% of the labeled dose due to poor mixing, the patient effectively receives an unintended overdose. Conversely, sub-potent product produces treatment failure that the patient may attribute to the drug not working, leading to unnecessary dose escalation. A 2019 analysis in JAMA Internal Medicine found that erectile dysfunction drugs were among the most commonly identified products in adverse event reports linked to compounding pharmacies, though causality attribution is difficult in that data set (Mullen et al., JAMA Intern Med 2019).

Special Populations: Where the Branded Data Are Clearer

Clinical trial evidence for vardenafil in special populations comes entirely from studies using branded Levitra. Extrapolating those findings to compounded products is reasonable only if bioavailability and dose accuracy are comparable.

Diabetes and Cardiovascular Disease

The Porst 2003 trial specifically enrolled men with type 1 and type 2 diabetes (N=452 in the diabetic subgroup). Vardenafil 20 mg improved the IIEF erectile function domain score by 6.6 points from a low baseline of 11.7 (scale 1-30), compared with 1.9 points for placebo (P<0.001) (Porst et al., 2003). The clinical message is that vardenafil works in diabetic ED, though absolute response rates are lower than in non-diabetic men.

A subsequent study in men with stable coronary artery disease (N=336, Vardenafil REDUCT trial, referenced in the ESC/EASD guidelines on diabetes and cardiovascular disease) found no increase in major adverse cardiovascular events compared with placebo during 12 weeks of treatment. The ACC/AHA 2012 guidance on sexual activity and cardiovascular disease states that PDE5 inhibitors are safe in men with stable CAD who are not on nitrates (Levine et al., Circulation 2012).

Older Men (Age 65+)

Vardenafil AUC increases by approximately 52% in men older than 65 compared with younger men, likely due to decreased hepatic CYP3A4 activity and reduced renal clearance (FDA label, Levitra). The starting dose recommendation for men 65 and older is therefore 5 mg, not 10 mg. Compounded pharmacies can provide 5 mg tablets, which is one area where compounding genuinely extends clinical utility.

Hepatic Impairment

In Child-Pugh A (mild) hepatic impairment, no dose adjustment is needed. In Child-Pugh B (moderate), the maximum recommended dose is 10 mg. Child-Pugh C (severe) is a contraindication to vardenafil use entirely (FDA label, Levitra).

Drug Interactions: The Same for Both Sources

Because compounded and branded vardenafil share the same CYP3A4-dependent metabolism, drug interaction risks are identical. The most clinically significant interactions include:

• Strong CYP3A4 inhibitors (ketoconazole 400 mg, ritonavir): Increase vardenafil AUC by up to 49-fold. Vardenafil is contraindicated with ritonavir and similar HIV protease inhibitors.
• Moderate CYP3A4 inhibitors (erythromycin, clarithromycin, fluconazole, grapefruit juice): Increase AUC 3-5-fold. Dose reduction to 5 mg is required.
• Alpha-blockers (tamsulosin, doxazosin): Can cause additive hypotension. Tamsulosin 0.4 mg is generally tolerated with vardenafil 5 mg, but higher alpha-blocker doses require caution and a minimum 6-hour spacing (FDA label, Levitra).

These interaction thresholds were established using branded Levitra in controlled pharmacokinetic studies. A compounded product with inaccurate potency could push a patient outside the safety margin of these interaction cutoffs.

Regulatory and Prescribing Considerations for Telehealth

Telehealth platforms frequently offer compounded vardenafil at low price points. The legal and regulatory field matters for both prescribers and patients.

The FDA has issued guidance stating that compounding a drug product that is essentially a copy of a commercially available product is generally not permitted for 503A pharmacies unless there is a documented patient-specific need (for example, an allergen to an excipient in the branded product) (FDA, Compounding Laws and Policies). The 2013 Drug Quality and Security Act codified this restriction. In practice, enforcement varies by state, and many telehealth-affiliated pharmacies operate in a gray zone.

Prescribers writing for compounded vardenafil should document the medical necessity clearly in the chart. Acceptable rationales include: required dose not commercially available, documented excipient allergy to a branded component, or significant cost barrier with no generic available. The Endocrine Society and the American Urological Association have not published specific guidance on compounded PDE5 inhibitors as of mid-2025, though the AUA's 2018 guideline on ED management recommends FDA-approved oral PDE5 inhibitors as first-line therapy (Burnett et al., J Urol 2018).

How to Choose: A Clinical Decision Framework

The decision between branded and compounded vardenafil comes down to four variables: regulatory assurance, dose requirements, excipient tolerance, and cost.

Choose branded Levitra or Staxyn if:

• The patient requires a standard dose (5, 10, or 20 mg) available commercially
• Insurance coverage or a GoodRx coupon brings cost to an acceptable level
• The patient has had a previous adverse reaction to a compounded product
• Maximum certainty of potency is needed (for example, a man with severe cardiovascular disease where a 2-fold dose error carries meaningful risk)

Compounded vardenafil may be appropriate if:

• The required dose is outside the 5/10/20 mg commercial range
• The patient has a documented allergy to an excipient in branded tablets (microcrystalline cellulose, crospovidone, colloidal silicon dioxide, titanium dioxide)
• Cost is a prohibitive barrier and no affordable generic exists in the local market
• The prescriber has access to a reputable 503B pharmacy that provides CoA documentation

The AUA guideline authors write: "Oral PDE5 inhibitors should be offered to men with erectile dysfunction as first-line therapy, given their efficacy, safety, and ease of use." (Burnett et al., J Urol 2018). That recommendation references FDA-approved agents. Compounded alternatives sit outside that evidence base, but may serve patients who cannot access or afford branded or generic versions.

Generic Vardenafil: The Middle Option

Generic vardenafil hydrochloride tablets (5 mg, 10 mg, 20 mg) became available in the U.S. After Bayer's exclusivity period ended. FDA-approved generics have passed bio-equivalence testing against the branded reference product, meaning their pharmacokinetic profile falls within the 80-125% confidence interval for AUC and Cmax. Generic vardenafil currently retails for $20-$60 per tablet at major chains and as low as $1.50-$3 per tablet through discount programs at select pharmacies. The generic option addresses the cost concern while preserving FDA bio-equivalence oversight, making it the most defensible first choice for cost-sensitive patients who need standard doses.